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Abstract
Background: Erythropoietin (Epo) administration has been reported to have tumor-promoting effects in anemic cancer
patients. We investigated the prognostic impact of endogenous Epo in patients with pancreatic ductal adenocarcinoma
(PDAC).
Methodology: The clinico-pathological relevance of hemoglobin (Hb, n=150), serum Epo (sEpo, n=87) and tissue
expression of Epo/Epo receptor (EpoR, n=104) was analyzed in patients with PDAC. Epo/EpoR expression, signaling,
growth, invasion and chemoresistance were studied in Epo-exposed PDAC cell lines.
Results: Compared to donors, median preoperative Hb levels were reduced by 15% in both chronic pancreatitis (CP,
p,0.05) and PDAC (p,0.001), reaching anemic grade in one third of patients. While inversely correlating to Hb (r=20.46),
95% of sEPO values lay within the normal range. The individual levels of compensation were adequate in CP (observed to
predicted ratio, O/P=0.99) but not in PDAC (O/P=0.85). Strikingly, lower sEPO values yielding inadequate Epo responses
were prominent in non-metastatic M0-patients, whereas these parameters were restored in metastatic M1-group (8 vs.
13 mU/mL; O/P=0.82 vs. 0.96; p,0.01)—although Hb levels and the prevalence of anemia were comparable. Higher sEpo
values (upper quartile $16 mU/ml) were not significantly different in M0 (20%) and M1 (30%) groups, but were an
independent prognostic factor for shorter survival (HR 2.20, 10 vs. 17 months, p,0.05). The pattern of Epo expression in
pancreas and liver suggested ectopic release of Epo by capillaries/vasa vasorum and hepatocytes, regulated by but not
emanating from tumor cells. Epo could initiate PI3K/Akt signaling via EpoR in PDAC cells but failed to alter their functions,
probably due to co-expression of the soluble EpoR isoform, known to antagonize Epo.
Conclusion/Significance: Higher sEPO levels counteract anemia but worsen outcome in PDAC patients. Further trials are
required to clarify how overcoming a sEPO threshold $16 mU/ml by endogenous or exogenous means may predispose to
or promote metastatic progression.
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Introduction
Anemia in cancer patients is a common symptom caused either
by the tumor itself or by cytotoxic treatment [1]. In response to
decreased hemoglobin (Hb) levels, the erythropoiesis-stimulating
agent erythropoietin (Epo) is produced in the kidney and
subsequently triggers erythropoiesis in the bone marrow and the
release of erythrocytes into the blood circulation, thus restoring the
Hb level. In cancer, this feedback mechanism seems to be
frequently disrupted, yielding an inadequate Epo response [2,3].
Administration of exogenous (recombinant human) rhEpo has
been approved for the correction of chemotherapy-induced
anemia in patients with non-hematopoietic malignancies, leading
to a reduction in blood transfusion requirements and an
improvement in quality of life [4–6]. According to current
guidelines, rhEpo can be administered to patients when dosed to
a target Hb level of less than 12 g/dl [7,8]. A meta-analysis
revealed no negative effect on tumor progression if rhEpo was
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trials have shown a higher risk of thrombovascular events,
decreased survival, and worse tumor control, calling into question
the safety and benefit of rhEpo treatment in patients with solid
tumors [8–10]. As summarized in a recent report, only one out of
19 clinical trials showed a positive impact of rhEpo on overall
survival (hazard ratio 1.3), whereas 10 studies did not demonstrate
any effect and 8 trials demonstrated worse survival for the Epo
arm [11].
Those data also turned attention to the role of endogenous Epo
in carcinogenesis [12–16]. Several studies have attempted to
explore direct effects of Epo on tumor cells and the possible
mechanisms for Epo-mediated tumor progression, but the data are
still controversial. Epo is a 30.4-kDa protein whose binding to the
transmembrane Epo receptor (EpoR) initiates signaling through
several transduction cascades: Jak2/STAT5, PI3K/Akt, ERK1/2,
phospholipase C and D, and NF-kB [17–20]. These pathways
appear to transduce Epo/EpoR signals not only in erythroid
precursors but also in malignant cells [12,14,21,22]. The published
data reporting an Epo-mediated impact on signaling, proliferation,
survival or invasion varied greatly with different tumor cells and
respective experimental conditions. The controversy over the
functionality of EpoR in malignant cells was heightened by the
discovery that cells may express multiple EpoR isoforms, with only
a very small fraction being at the cell surface [23–25]. Importantly,
the finding that the widely used anti-EpoR antibody C-20 cross-
reacts with heat-shock protein 70 (HSP70) called into question C-
20-based findings of EpoR in tumor cells and tissues [26,27].
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive and deadliest malignancies, and also requires the
highest rate of transfusions among cancer patients undergoing
cytotoxic therapies [28–30]. Chemotherapy is standard in the
adjuvant and palliative settings, and aggravates anemia. Consid-
ering the reported negative effects of rhEpo treatment, the use of
rhEpo to correct anemia in PDAC patients should be carefully
assessed. In the present study, we hypothesized that the level of
endogenous Epo might be a risk factor for PDAC progression in
both anemic and non-anemic patients, and therefore investigated
whether and how the individual Epo response can determine the
degree of cancer aggressiveness in PDAC patients. The expression
of Epo/EpoR in blood and tissue samples was analyzed in the
context of clinico-pathological parameters in donors, chronic
pancreatitis (CP) patients, and PDAC patients. The possibility of
direct pro-malignant effects and increased chemoresistance was
assessed in PDAC cells exposed to rhEpo.
Materials and Methods
Patients and specimens
The study was conducted in accordance with the Helsinki
Declaration; specimen collection was approved by the ethical
committee of the University of Heidelberg (votes 301/2001 and
159/2002) and written informed consent was obtained from the
patients. The study was performed with tissue and blood samples
obtained from patients admitted to the Department of General,
Visceral and Transplantation Surgery, University Hospital
Heidelberg [30], between February 2002 and February 2005 for
surgical treatment of PDAC (n=150) or chronic pancreatitis (CP,
n=42). Diagnoses were established by a pathologist according to
the World Health Organization (WHO) classification. Clinical
stages are given as defined by the Union for International Cancer
Control (AJCC/UICC; 7
th Edition, 2009). The normal pancreatic
specimens (n=29) were collected during donor organ procure-
ment if no suitable recipient had been found for the donor’s
pancreas through the Eurotransplant program. The general
characteristics of the patients are given in Table 1: the blood
specimens were processed to measure levels of Hb and Epo,
whereas tissues were used for analyses of Epo/EpoR mRNA and
protein expression. The exact number of analyzed specimens in
each study group is also shown in the figure legends.
Hematological analyses
Hb values were determined in pre-operative blood samples of
PDAC (n=150) and CP (n=42) patients and used to diagnose
anemia as defined by the European Organization for the Research
and Treatment of Cancer (EORTC) at Hb levels #12 g/dl. Epo
levels in sera of PDAC (n=87) and CP (n=13) sub-cohorts as well
as healthy volunteers (n=9) were analyzed using the IMMULI-
TEH detection system and Epo kit according to the manufacturer’s
instructions (DPC Biermann GmbH, Bad Nauheim, Germany).
The adequacy of Epo response to a given degree of anemia was
defined by a standard method calculating observed to predicted
sEPO ratio (O/P) [3,31–34]. The regression equation log(Epo)=
1.6662(0.041476Hb) was established with sEpo and Hb values
from 22 non-cancerous reference subjects (donors and CP patients)
and then used to predict Hb-adequate Epo values in the
individuals with PDAC. The mean O/P ratio in reference subjects
was 1.0060.19 (95% confidence interval: 0.92–1.09).
Cell cultures and Epo treatment
The authenticity of established pancreatic cell lines AsPC-1,
BxPC3, Colo357, Capan-1, MiaPaCa-2, PANC-1, Su8686, and
T3M4 was certified by DSMZ (German Collection of Microor-
ganisms and Cell Cultures, GmbH, Braunschweig, Germany). The
cells were cultured under hypoxic (0.75% O2+10% CO2;i na
chamber produced by Billups-Rothenberg, Del Mar, CA) or
normoxic (21% O2+5% CO2) conditions in RPMI-1640 (PAA,
Co ¨lbe, Germany) supplemented with 0–10% of fetal bovine serum
(FBS, PAN Biotech, Aidenbach, Germany). The IL-3-dependent
pro-B cell line Ba/F3 or the fibroblast cell line NIH/3T3 were
stably transduced with either pMOWS-hEpoR or the empty
vector (mock-transduction) and served as a positive or negative
control, respectively. Ba/F3 cells were maintained with 10% of
WEHI-3B supernatant as a source of IL-3. [20].
The cells were exposed to rhEpo (ErypoH, Ortho Biotech,
Janssen-Cilag GmbH, Neuss, Germany) at final concentrations of
1–50 U/ml. Depending on the type of experiment, the cells were
harvested at different time points, as indicated in the main text.
The signal transduction studies included pretreatment of cells with
the PI3K-inhibitor LY2940002 (Sigma, Deisenhofen, Germany) at
a final concentration of 30 mM added 30 min prior to the
experiments or addition of the monoclonal anti-EpoR antibody
(MAB307, Table 3) at 30 mg/ml as previously described to
antagonize binding of Epo to the EpoR [16,20].
Analysis of Epo and EpoR mRNA expression
mRNA was isolated from tissues and cells, converted to cDNA, and
amplified by PCR (real-time quantitative qRT-PCR) using kits and
automated equipment from Roche Applied Sciences (RAS, Mann-
heim,Germany) asdescribed previously [35]. Thenumber ofEpo and
EpoR transcripts in the samples measured in the LightCyclerH (RAS)
with commercially available kits (Search-LC, Heidelberg, Germany)
was normalized to the expression of the housekeeping gene cyclophilin
B. The final data are presented as number of Epo or EpoR transcripts
per 10,000 CPB copies (10 kCPB).
To check the expression of EpoR isoforms, PCR was performed
using primers previously published by Arcasoy et al., as listed in
Table 2 [24]. PCR products were separated by agarose gel
Epo/EpoR in PDAC
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A. General characteristics of the groups
Groups No. of patients
Age [years]
Median (IQR)
Hb [g/dl]
Median (IQR)
Serum Epo
[mU/ml]
Median (IQR)
O/P ratio
Mean±SD
Epo mRNA
[copies/10
kCPB]
Median (IQR)
EpoR mRNA
[copies/10
kCPB]
Median (IQR)
Survival
[months]
Median
Donor 38 50.5 (34.0–59.8) 15.1 (13.9–16.3)
n=9
12.7 (8.7–13.3)
n=9
1.0160.12 20 (13–25)
n=29
174 (124–281)
n=29
Male 25 46.0 (30.5–60.5) 15.9 (14.9–16.3)
n=6
12.9 (11.3–13.7)
n=6
1.0660.10 16 (10–25)
n=19
148 (104–255)
n=19)
Female 13 52.0 (43.5–60.5) 13.8 (13.5–13.9)
n=3
9.2 (8.1–12.7)
n=3
0.9060.08 22 (15–26)
n=10
240 (152–544)
n=10)
CP 42 47.0 (38.0–54.0) 12.9 (12.0–14.2)
n=42
12.0 (8.9–18.8)
n=13
0.9960.23 7 (2–13)
n=29
351 (219–533)
n=29)
Male 31 50.0 (37.0–56.0) 13.6 (12.3–14.5)
n=31
11.3 (8.0–15.1)
n=10
0.9260.17 9 (2–16)
n=21
355 (219–533)
n=21)
Female 11 44.0 (40.0–48.0) 11.8 (10.8–12.9)
n=11
18.2 (13.7–74.4)
n=3
1.2560.25 5 (2–9)
n=8)
322 (218–538)
n=8)
PDAC 150 65.0 (56.0–70.3) 13.0 (11.9–13.9)
n=150
9.8 (5.6–15.2)
n=87
0.85+0.24 1 (0–2)
n=104
176 (94–302)
n=104)
18.0
Male 80 63.5 (56.0–70.8) 13.7 (12.0–14.5)
n=80
8.5 (5.3–15.5)
n=42
0.8760.25 0 (0–4)
n=60
149 (95–281)
n=60)
17.0
Female 70 65.0 (57.8–70.3) 12.6 (11.8–13.5)
n=70
10.0 (6.0–15.3)
n=45
0.8460.24 1 (0–2)
n=44
183 (94–418)
n=44)
18.5
B. PDAC sub-cohorts
Study cohort PDAC Stage I/IIA Stage IIB Stage III Stage IV Anemic Non-anemic
Total No. of patients 150 25 85 9 31 43 107
Age [years;
median (IQR)]
65 (56–70) 62
(55–73)
66
(59–71)
58
(56–65)
64
(58–70)
65
(57–73)
65
(56–70)
Hb [g/dL;
median (IQR)]
13.0
(11.9–13.9)
12.9
(12.3–13.9)
13.2
(12.0–14.2)
12.6
(10.3–13.2)
12.8
(11.5–13.9)
11.4
(10.3–11.8)
13.6
(12.8–14.4)
Anemic 29% 20% 27% 44% 35%
Survival
[months; median]
18.0 28.5 18.0 17.5 10.0 11.0 19.0
Serum No. of patients 87 16 44 4 23 31 56
Age [years;
median (IQR)]
65
(58–70)
62
(55–72)
66
(60–70)
62
(57–66)
64
(58–71)
64
(58–72)
66
(57–70)
Hb [g/dL;
median (IQR)]
12.8
(11.8–13.9)
12.9
(11.9–13.9)
12.9
(11.8–14.1)
12.4
(10.6–13.3)
12.3
(11.5–13.7)
11.5
(10.7–11.8)
13.7
(13.9–14.4)
Anemic 36% 25% 34% 30% 43%
sEpo [mU/mL;
median (IQR)]
9.8
(5.6–15.2)
9.1
(4.6–11.6)
7.3
(5.0–15.5)
8.8
(5.4–10.9)
12.5
(8.7–18.4)
14.9
(8.4–22.2)
7.5
(4.9–11.0)
O/P [mean6SD] 0.8560.24 0.7960.21 0.8260.26 0.7760.16 0.9660.22 0.9560.24 0.8060.23
Survival
[months; median]
17.0 32.0 18.0 9.0 8.5 13.5 18.0
Tissue No. of patients 104 19 68 5 12 24 80
Age [years;
median (IQR)]
65
(56–71)
62 (54–73) 66
(58–71)
56
(55–64)
61
(55–67)
67
(57–76)
64
(56–70)
Hb [g/dL;
median (IQR)]
13.3
(12.2–14.2)
12.9
(12.2–13.7)
13.3
(12.0–14.3)
12.6
(10.2–14.6)
13.9
(13.0–14.4)
11.5
(10.2–11.9)
13.7
(12.9–14.5)
Anemic 23% 21% 25% 40% 8%
sEpo [mU/mL;
median+IQR]
7.0 (4.5–10.0)
n=41
9.1 (4.2–16.3)
n=10
6.1 (4.6–9.9)
n=27
n/a 7.6 (3.8–8.7)
n=4
9.2 (4.7–23.6)
n=12
6.5 (4.5–9.1)
n=29
Survival
[months; median]
22.0 30.0 18.0 30.0 12.0 13.0 23.0
doi:10.1371/journal.pone.0023151.t001
Epo/EpoR in PDAC
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bromide.
Testing of anti-EpoR antibodies
Recent studies revealed a lack of specificity for C-20 and other
anti-EpoR antibodies due to cross-reactivity with HSP70 [26]. In
the present study we tested the ability of 5 different antibodies
(Table 3) to detect EpoR by immunoprecipitation, Western blot,
FACS and immunohistochemistry. To differentiate between
specific and non-specific binding, we used i) hEpoR- or mock-
transduced BaF/3 and NIH/3T3 cells, ii) bone marrow specimens
and iii) soluble EpoR (sol-EpoR) for blocking set-ups. As a result,
the monoclonal 3D10 antibody recognizing an extracellular
domain of EpoR (Sigma) was chosen for the detection of EpoR
in different assays (except flow cytometry).
Immunohistochemistry
Immunohistochemistry was performed as previously described
[36]. Briefly, 4 mm-thin paraffin-embedded tissue sections were
deparaffinized and rehydrated in progressively decreasing con-
centrations of ethanol. After retrieval of antigens by boiling in
10 mM citrate buffer, the sections were subsequently exposed to
3% H2O2 in methanol, universal blocking solution (Powerblock;
Biogenix, San Ramon, CA, USA), and the goat anti-hEpo or
mouse anti-hEpoR primary antibodies (Table 3). Sections
incubated with goat IgG or mouse IgG2b (Dako, Glostrup,
Denmark) served as negative isotype controls for n-19 and 3D10
antibodies. The anti-Epo antibody was validated by showing
immunopositivity of the tubular epithelial cells in the kidney (not
shown). For EpoR, the specificity of the staining was additionally
controlled by incubation of the sections with the anti-EpoR
antibody pre-treated with a 5-fold excess of soluble EpoR (sol-
EpoR). After overnight incubation at 4uC, the secondary
horseradish peroxidase (HRP)-labeled antibodies were applied at
room temperature for 45 min (donkey anti-goat IgG for EPO;
Santa Cruz Biotechnology/SCBT, Heidelberg, Germany, or
polymer-conjugated goat anti-mouse IgG for EpoR; EnVi-
sion
TM+System, Dako). The HRP-reaction product was visualized
using a DAB/H2O2 substrate mixture kit (EnVision
TM, Dako) and
sections were counterstained with Mayer’s hematoxylin.
Immunoprecipitation (IP) and Western blot
Cells were lysed in 1% Nonidet P-40 lysis buffer (1% NP-40,
150 mM NaCl, 20 mM Tris at pH 7.4, 10 mM NaF, 1 mM
ZnCl2 at pH 4.0, 1 mM EDTA at pH 8.0, 1 mM MgCl2, 10%
glycerol, 1 mM Na3VO4) supplemented with proteinase inhibitor
cocktail (Roche) [16,20]. For IP, the lysates were incubated
20 minutes on ice, cleared by centrifugation, and incubated with
a primary antibody (table 3) and protein A-sepharose beads at
4uC overnight. The immunocomplexes were washed with lysis
buffer and TNE buffer (10 mM Tris at pH 7.4, 100 mM NaCl,
1 mM EDTA at pH 8.0, 100 mMN a 3VO4). Protein samples
were denatured at 95uC for 2 min, separated using a 10%
polyacrylamide SDS gel. For non-IP Western blot analysis, 40 mg
of protein from cell lysates or 2 ml of sol-EpoR (50 mg/ml, Sigma)
were separated using 4–12% gel (NuPAGE, Invitrogen GmbH,
Darmstadt, Germany). Upon transfer to a nitrocellulose mem-
Table 2. Overview of EpoR RT-PCR primers [24].
Primer EpoR gene location Sequence Product size (bp) Isoform
EpoR_FL1 Exon 8 sense GCTCCCAGCTCTTGCGTCCA 316 Full length EpoR
EpoR_FL2 Non-coding antisense TCGCCATCCCTGTTCCATAA
EpoR_FL3 Exon 7 sense ATCCCGAGCCCAGAGAGCGAGT 137 Full length EpoR
EpoR_FL4 Exon 8 antisense AGGGAAGCAGGTGGGTCCTCCGTG
EpoR_S5 Intron 5 sense GGAGCCAGGGCGAATCACGG 204 Sol-EpoR (Intron 5 unspliced)
EpoR_S6 Exon 7 antisense GCCTTCAAACTCGCTCTCTG
doi:10.1371/journal.pone.0023151.t002
Table 3. Primary antibodies.
Antigen Antibody type Application* and Dilution Manufacturer
hEpoR (C-20, cytoplasmic domain) Rabbit polyclonal IB, 1:2000–1:5000 Santa Cruz Biotechnologies, Heidelberg, Germany
hEpoR (M-20, cytoplasmic domain) Rabbit polyclonal IB, 1:500; IP, 1:250 Santa Cruz Biotechnologies, Heidelberg, Germany
hEpoR (clone 38409, extracellular domain) Mouse monoclonal FC, 10 mL/2610
5 cells R&D Systems, Minneapolis, MN, USA
Mouse IgG2b Isotype control Mouse monoclonal FC, 20 mL/2610
5 cells R&D Systems, Minneapolis, MN, USA
hEpoR (clone MAB307, extracellular domain) Mouse monoclonal BA, 30 mg/ml R&D Systems, Minneapolis, MN, USA
hEpoR (3D10, extracellular domain) Mouse monoclonal IF, 1:25; IB, 1:500; IHC, 1:100; IP, 3 mL Sigma, Deisenhofen, Germany
Epo (n-19) Goat polyclonal IHC 1:50 Santa Cruz Biotechnologies, Heidelberg, Germany
Akt Rabbit polyclonal IB, 1:1000 Cell Signaling Technology, Inc., Danvers, MA, USA
Phospho-Akt (ser473) Rabbit polyclonal IB, 1:1000 Cell Signaling Technology, Inc., Danvers, MA,USA
STAT5 (C-17) Rabbit polyclonal IP, 5 mL; IB, 1:1000 Santa Cruz Biotechnologies, Heidelberg, Germany
Phospho-STAT5 (Tyr 694) Rabbit polyclonal IB, 1:1000 Cell Signaling Technology, Inc., Danvers, MA,USA
*BA, blocking antibody; IB, immunoblot; IF, immunofluorescence; IHC, immunohistochemistry; IP, immunoprecipitation; FC, flow cytometry.
doi:10.1371/journal.pone.0023151.t003
Epo/EpoR in PDAC
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blocked with 5% SlimFast powder (Allpharm, Messel, Germany)
in TBS buffer with 0.05% Tween-20, exposed to primary
antibodies (Table 3) overnight at 4uC, and incubated with
corresponding anti-rabbit or anti-mouse HRP-conjugated sec-
ondary antibodies (1:2,000; Santa Cruz, Heidelberg, Germany)
for 1 h at room temperature. The signal was visualized using
Amersham ECL detection reagents (GE Healthcare, Buckin-
ghamshire, UK).
Flow cytometry
Cells were resuspended in FACS buffer (PBS, 2% FBS, 0.01%
sodium azide), blocked with FCR Blocking Reagent/human
(Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) and
incubated with FITC-labelled anti-EpoR antibody (clone 38409,
extracellular domain) or IgG2b isotype control immunoglobulin
(both R&D Systems, Minneapolis, MN, USA, table 3). FACS
analysis was performed with the FACS LSR-II system (BD
Biosciences, Heidelberg, Germany).
Functional assays (cell invasion, growth and
chemoresistance)
To evaluate cell invasion, upper chambers of Biocoat Matrigel-
TM invasion chambers (8 mm pore size/PET membrane, BD)
were seeded with serum-starved (24 h) cells. The bottom chamber
contained RPMI-1640 with Epo at 1–50 U/ml. After 24 h, the
membranes with invaded cells were fixed in 70% ethanol and
stained with Mayer’s hemalum solution (Merck KGaA, Darm-
stadt, Germany). The cells were counted in 3 visual fields under
100-fold magnification.
To evaluate growth and chemoresistance, a 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was per-
formed. The cells were seeded in 96-well plates and incubated with
various concentrations of Epo (1–50 U/ml), with or without the
chemotherapeutic agents 5-fluorouracil (5-FU) (Sigma) and
gemcitabine (Fresenius, Bad Homburg, Germany) at 0.1–10 mM.
MTT reagent was added after 48 h of incubation, and the
accumulation of formazan in live cells was determined upon
solubilisation of the product and measuring optical density at
570 nm. All assays were performed in triplicate.
Statistical analyses
Data were analyzed with GraphPad Prism (GraphPad Software,
La Jolla, CA) and SAS (version 9.1; SAS Institute, Cary, NC,
USA). The quantitative variables Hb, sEpo, tissue Epo/EpoR
mRNA are presented as dot blots or box and whisker plots
displaying the median, interquartile range (IQR), and the 5
th and
95
th percentiles. Significance of differences between groups was
assessed by the nonparametric Mann-Whitney U test (to compare
2 groups) or the Kruskal-Wallis with Dunn’s tests (to compare 3
and more groups). Linear correlation analyses were performed
using the Spearman test. Multivariate Cox regression analysis was
performed to identify independent prognostic markers among
parameters given in Table 1. To analyze the impact of Epo levels
on the overall survival, the corresponding quartiles were used to
divide patients into groups. The overall survival from the date of
initial surgery was estimated using the Kaplan-Meier method. The
observations on 14 PDAC patients still alive at the end of the
follow-up period in October 2010 were censored. Differences
between survival curves were analyzed using the log-rank test. For
all assays, two-sided p values were computed and a difference was
considered statistically significant at p#0.05 (*), p,0.01(**) or
p,0.001(***).
Results
Higher levels of circulating Epo are associated with a
worse prognosis in PDAC
The median Hb level in patients with PDAC was 15% lower
than in donors (p,0.001, Figure 1A and Table 1). Likewise, in
patients with CP, median Hb level was significantly decreased
(p,0.05). A third of patients with PDAC or CP were mildly
anemic (#12 g/dl) prior to surgical resection. 95% of the sEpo
values in PDAC patients were within the known normal range (5–
34 mU/ml) and did not differ significantly from those in donor
and CP groups (median sEPO: 9.8 mU/ml vs. 12.7 and
12.0 mU/ml, respectively; p=0.15; Figure 1B). Nevertheless,
multivariate analysis revealed that the level of endogenous sEpo –
but not Hb–was an independent negative prognostic factor for
PDAC patients (hazard ratio, HR 2.20, p=0.01). Patients with
sEpo.16 mU/ml (sEpo
high, upper quartile) had a significantly
shorter median survival (10.0 vs. 16.7 months; p=0.03) and
increased 3-year mortality rates (100% vs. 75%, Figure 1C). The
proportions of sEpo
high individuals in the subgroups with
localized (M0, UICC stages I–III) and metastatic (M1, UICC
stage IV) disease stages were comparable (M0 vs. M1: 20.3% vs.
30.4%; p=0.39), even though tumor stage (but not grade, G3 vs.
G1/2, p=0.74) was another independent prognostic factor in
PDAC (UICC I+IIa vs. IIb: HR 0.43, p=0.030; III+IV vs. IIb:
HR 2.09, p=0.020).
Median sEpo level in patients with stage IV was approxi-
mately double that of stage I–III patients (12.5 and 7.7 mU/ml;
p,0.01, Figure 1D) but comparable to donor and CP groups
(Figure 1B). Lower Epo levels in stage I–III patients could be
attributed either to the lack of anemia in this group or to an
inadequate Epo response to a given degree of anemia. Yet Hb
values (Figure 1E) and the prevalence of anemia were
comparable between different stages (UICC I–III vs. IV: 33%
vs. 43%, p=0.45; Table 1). Despite an inverse correlation
between sEPO and Hb in PDAC patients (Spearman r=20.46,
p,0.001; Figure 1F), the Epo response in PDAC patients was
lower than expected (mean O/P ratio: 0.8560.24; 95%
confidence interval [CI]: 0.80–0.91). However, this impaired
Epo response was caused primarily by lower sEpo level
consequently leading to reduced O/P ratios in stage I–III
patients (mean observed to predicted ratio (O/P)=0.8260.26,
95%CI 0.76–0.89) as contrasted by higher sEpo values yielding
an adequate Epo responses in CP (O/P=0.9960.23, 95%CI
0.85–1.13; p,0.05) and PDAC/stage IV cohorts (OP=0.966
0.22; 95%CI 0.89–1.08; p,0.01).
Aberrant ectopic expression of Epo in pancreatic diseases
The restoration of EPO response in PDAC/stage IV patients
might reflect a ‘passive’ elevation of sEPO levels through ectopic
(Hb- and kidney-independent) Epo release. Quantitative mRNA
analysis confirmed the ability of the pancreas to produce Epo, but
disclosed a progressive loss of Epo mRNA expression in CP by
.70% and in PDAC by .95% (Figure 2A). This pattern
suggested that Epo-producing islets [37] were disappearing
together with the vanishing parenchyma (Figure 3A), and that
accumulating PDAC cells were unable to compensate for islet-
related losses. Indeed, immunohistochemical staining of PDAC
samples showed that Epo-specific antibodies did not bind to the
tumor cells (Figure 3B) - except for the rare foci which displayed
Epo-positive intracellular vacuoles (Figure 3C). Furthermore,
constitutive or hypoxia-stimulated Epo transcription was barely
detectable in established PDAC cell lines, except in T3M4 cells
showing robust Epo mRNA transcription and its 3-fold up-
Epo/EpoR in PDAC
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PDAC cells were an unlikely source of ectopic Epo. In contrast,
Epo-positive endothelium [21] was frequently found in peripheral
capillaries and vasa vasorum of the bigger vessels in PDAC and also
in CP (Figure 3D) but not in donor pancreata (not shown).
Although pancreatic tumor samples of stage IV patients showed
statistically significant elevation of Epo mRNA levels compared to
the non-metastatic group, the measured values were extremely low
(Figure 2C). Furthermore, no significant correlation could be
observed between pancreatic Epo mRNA and sEpo in PDAC
patients (n=41; Spearman r=20.18, p=0.26). Thus, we
investigated whether a distant organ affected by metastasis could
serve as source for ectopic Epo. Metastasized to the liver tumor
cells rarely expressed Epo. However, Epo-negative metastases
Figure 2. Aberrant expression of Epo mRNA in pancreatic tissues and tumor cells. (A) qRT-PCR analysis of pancreatic tissues revealed
gradual loss of Epo mRNA expression in diseased pancreata. (B) Except for T3M4, low levels of Epo mRNA expression were found in pancreatic tumor
cell lines exposed to or not exposed to 0.75%-hypoxia. Nx=normoxia; Hx=Hypoxia. (C) Barely detectable yet elevated Epo mRNA expression was
found in pancreatic specimens obtained from stage IV PDAC patients (n=12) compared to stage I–III (n=92) patients. The numbers in panels A and C
depict median levels. Statistically significant differences are labeled by asterisks: p#0.05 (*), p,0.01(**) or p,0.001(***).
doi:10.1371/journal.pone.0023151.g002
Figure 1. Level of sEpo but not Hb was associated with a worse prognosis in PDAC. The differences in preoperative levels of Hb (A) and
sEpo (B) in blood of donors (n=9), CP (n=13) and PDAC (n=87) patients (see table 1A and 1B for full information regarding studied sub-cohorts). (C)
Kaplan-Meier analysis of survival data showing that a higher level of sEpo (upper quartile in panel B, $16 mU/ml) was associated with shorter survival
of PDAC patients; ms=median survival time, in months. (D) Reduced sEpo levels in stage I–III PDAC patients (n=64) and their restoration in
metastatic patients (n=23). (E) Prevalence of anemia and Hb values were equally distributed during PDAC progression. (F) sEpo inversely correlated
with Hb in PDAC. The numbers in panels A, B, D and E depict median levels. Statistically significant differences are labeled by asterisks: p#0.05 (*),
p,0.01(**) or p,0.001(***).
doi:10.1371/journal.pone.0023151.g001
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featuring a remarkable gradient of the coloration that faded away
in distal hepatocytes (Figure 3E–F). In non-metastatic parenchy-
ma, the cytoplasmic Epo signal was detected in hepatocytes
located near portal areas or inflammatory infiltrates (not shown).
qRT-PCR analysis confirmed the ability of normal (25615
copies/10 kCPB, n=6 organ donor specimens) and metastatic
(1264 copies/10 kCPB, n=12 biopsies) livers to express Epo.
Thus, non-malignant hepatocytes emerged as a potential ectopic
source of Epo, possibly being spatially controlled by the tumor
cells.
Variability of the EpoR expression in cancerous pancreata
Apparently, increased production, release, and delivery of Epo
by non-malignant structures could create multiple Epo-rich niches.
Their potential direct impact on tumor cells was assessed by
studying i) the expression of EpoR in PDAC cells, ii) Epo-induced
down-stream signaling, and iii) functional consequences of
exposure to Epo.
In agreement with previous observations reporting that most of
the EpoR was retained in the endoplasmic reticulum [38], we
detected strong cytoplasmic staining of erythroid cells in bone
marrow, with decrease of positivity after pre-incubation of
Figure 3. Ectopic sources of Epo in tissues of patients with pancreatic diseases. (A) Remnants of Epo-producing islets in degrading CP-
parenchyma. (B) Epo-negativity of tumor cells in primary pancreatic lesion, except for sporadic focal staining observed in intracellular vacuoles of
tumor cells (C, arrows and inset). Peripheral capillaries (C, arrowheads) and vasa vasorum (D, arrowheads) of bigger vessels frequently demonstrated
Epo positivity in PDAC and CP. (E, F) In liver, cytoplasmic staining of hepatocytes was strong in areas directly bordering Epo-negative metastatic
tumor cells and inflammatory infiltrates, but faded away distally, thus pointing to the spatially regulated de novo synthesis and creation of multiple
Epo-rich niches. Insets in A, D and E depict negative (isotype IgG) controls; insets in C and F show high-magnification (6630) images of staining
patterns in intracellular vacuoles of tumor cells and cytoplasm in hepatocytes.
doi:10.1371/journal.pone.0023151.g003
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tissues revealed highly heterogeneous patterns of immunopositiv-
ity (Figure 4C–E). Whereas 37% (7/19) of specimens showed no
staining, cytoplasmic signal was detected in the remaining cases,
ranging from a weak sporadic to a strong abundant EpoR-
positivity in 26% and 37% of cases, respectively. We could not
identify characteristic distinctions between EpoR-positive and
EpoR-negative cells (e.g., specific localization within the tumor or
near vessels), nor was there a correlation with lymph node-
positive N1 status of tumor or grade of tumor differentiation. In
addition, few non-malignant structures within PDAC tissue
samples also demonstrated EpoR immunopositivity (Figure 4F).
The tissue expression of EpoR in normal pancreas and PDAC
tissues was further confirmed through mRNA analysis
(Table 1).
The variability of EpoR expression was also observed in
established pancreatic tumor cell lines. All eight studied cell lines
expressed EpoR mRNA and showed a 2- to 10-fold up-regulation
in hypoxic conditions (Figure 5A). The level of EpoR expression
under normoxia ranged from 10 copies/10 kCPB in BxPC3 cells
to over 300 copies/10 kCPB in PANC-1 cells. PANC-1 was the
only cell line in which EpoR protein was detectable at the cell
surface by flow cytometry using anti-EpoR antibodies (Figure 5B),
whereas immunoprecipitation with the 3D10 antibody followed by
immunoblotting with the C-20 antibody also allowed detection of
EpoR protein in the cells with lower mRNA expression, such as
MiaPaCa-2 and BxPC3 (Figure 5C).
Epo activates PI3K/Akt but not Jak2/STAT5 signaling in
PDAC cells
Two principal signaling pathways activated upon binding of
Epo to EpoR are the Jak2/STAT5 and PI3K/Akt phosphoryla-
tion cascades. Upon stimulation of serum-starved cells with 50 U/
ml of Epo, phosphorylation of STAT5 was observed in hEpoR-
Figure 4. Detection of EpoR-positive tumor cells in PDAC pancreata. (A) Staining of erythroid precursor cells in human bone marrow with
anti-EpoR 3D10 antibody (inset, 6400) and (B) loss of staining if the anti-EpoR antibody has been pre-incubated with soluble EpoR (sol-EpoR). (C, E)
Varying intensity and focal character of EpoR-immunopositivity of tumor cells in PDAC tissues (arrows) and (D) blocking of EpoR signal with sol-EpoR.
(F) Sporadic EpoR-immunopositivity of non-malignant structures within a PDAC sample and blocking of EpoR signal with sol-EpoR (inset).
doi:10.1371/journal.pone.0023151.g004
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but in none of three studied pancreatic tumor cell lines. Epo was
unable to either initiate STAT5 activation in MiaPaCa-2 and
BxPC3 cells, or to potentiate STAT5 phosphorylation in PANC-1
cells which displayed strong constitutive phosphorylation of
STAT5 despite prolonged 24 h serum starvation (Figure 6A). In
contrast, dose-dependent phosphorylation of Akt was observed in
serum-starved PANC-1 cells showing a very weak level of
constitutive Akt activation (Figure 6B, left). This induction could
be blocked by the anti-EpoR antibody MAB307 or by the specific
PI3K/Akt pathway-inhibitor LY294002. Potentiation of Akt
signaling in primed (1% serum) PANC-1 cells was not possible
(Figure 6B, right). Thus, the PI3K/Akt pathway but not the Jak2/
STAT5 pathway was able to transmit the Epo signal in non-
primed PDAC cells.
Expression of the soluble EpoR- isoform in PDAC cells
and lack of the functional responses to rhEPO
The behavior of PDAC cells in an Epo-rich environment (0–
50 U/ml) has been studied by assessing the proliferative, invasive
and survival potential of three PDAC cell lines (PANC-1, MiaPaCa-
2,BxPC3)under conditions of oxygen deprivation,serum starvation
and chemotherapeutic treatment (5-fluorouracil and gemcitabine).
Neither of these experiments demonstrated any statistically
significant pro-malignant or pro-survival effects of exogenously
added rhEpo (data not shown). Although we could not exclude the
inertness of Epo towards the tumor cells under the studied
conditions, we hypothesized that a soluble isoform of EpoR (sol-
EpoR) might block Epo signaling by binding of Epo and thereby
decreasing receptor-mediated signal transduction. Such a sol-EpoR
variant is known to rapidly accumulate up to the nanogram level in
the growth medium of tumor cells as soon as 1.5 hours after
medium renewal [39]. Probably, sol-EpoR accumulation could
occur in the long-term functional studies but not in the short-term
signaling experiments. RT-PCR analysis showed varying levels of
the alternatively spliced mRNA transcripts coding for the sol-EpoR
isoform in all eight studied cell lines (Figure 6C). We concluded that
EpoR-positive PDAC cells are equipped to respond to Epo but sol-
EpoR might antagonize Epo signaling, with higher Epo having a
greater chance of overcoming sol-EpoR and reaching tumor cells in
vitro and in sEpo
high patients.
Discussion
Today, the safety of Epo in the oncologic setting is still an issue
of concern. Several studies have attempted to elucidate whether
Figure 5. Expression of EpoR in PDAC cells. (A) qRT-PCR analysis revealed constitutive EpoR mRNA expression in all studied cancer cell lines and
its strong up-regulation under hypoxic conditions. Nx=normoxia, Hx=hypoxia. (B) EpoR was detectable on the surface of hEpoR-transduced Ba/F3
cells and PANC-1 cells by flow cytometry analysis using an FITC-labeled antibody. Mouse IgG2b was used as a negative control. (C) Left panel:
detection of the full-length EpoR protein in cell lysates of hEpoR-transduced NIH/3T3 cells and the recombinant sol-EpoR protein using the 3D10-
antibody by Western blot analysis (with GAPDH as loading control). Right panel: detection of EpoR in pancreatic tumor cells and hEpoR-NIH/3T3 by
immunoprecipitation with the 3D10-antibody followed by immunoblotting with the C-20 antibody.
doi:10.1371/journal.pone.0023151.g005
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do not clearly explain the underlying mechanisms [14]. Although
the findings of mRNA transcripts coding for multiple EpoR
isoforms are abundant and convincing, the observation regarding
cell surface expression, down-stream signaling and functional
consequences are rather rare and controversial [23,27]. In the
present study, we investigated the effects of endogenous and
exogenous Epo on PDAC progression and chemoresistance.
We showed that sEpo
high ($16 mU/ml)—but not Hb—was an
independent, negative prognostic survival marker in PDAC.
Although the physiological Epo response seems to be impaired
in PDAC, ectopic non-malignant sources of Epo such as
hepatocytes and capillaries surfaced as potential candidates for
restoring sEpo levels in the circulation and for creating Epo-rich
niches at different locations. Since we succeeded in proving EpoR
expression at the mRNA and protein level, as well as EpoR
initiation of PI3K/Akt signaling in PDAC cells, a direct impact on
the tumor cells emerged as a highly probable event to be
associated with the negative clinical associations seen in sEpo
high
PDAC patients. However, we could not track any effects of Epo on
proliferation, invasion or chemoresistance. PI3K/Akt activation
by Epo has recently been reported in other malignancies and was
associated with either antiapoptotic or proliferative effects or with
no impact on cellular proliferation [40–42]. Since Epo did not
affect PDAC cells even under hostile environmental conditions
(hypoxia, serum starvation), one could suggest that neither high
sEpo levels creating Epo-rich niches, nor administration of rhEpo
will provoke pancreatic malignancy.
The clinical impact and interpretation of these results are
complex, however. First, the minimal Epo concentrations needed
to demonstrate Akt-phosphorylation (10 U/ml) in vitro were 1000-
fold higher than normal blood concentrations in humans, ranging
from 5 to 34 mU/ml [18,31,32], although we cannot exclude
higher levels of Epo accumulating near tumor cells in tissues.
Figure 6. Activation of PI3K/Akt but not Jak2/STAT5 signaling in PDAC cells exposed to Epo. (A) Phosphorylation status of Stat5 was
assessed in serum-starved pancreatic tumor cells and hEpoR-transduced NIH/3T3 cells stimulated with 50 U/ml erythropoietin (Epo) for 10 min. Clear
accumulation of pSTAT5 was observed in hEpoR-NIH/3T3 but not in mock-transduced NIH/3T3 cells or in PDAC cells, independent of the level of
constitutive pSTAT5 activation. (B) Phosphorylation status of Akt was assessed in serum-starved (left panel) or non-starved (right panel) PANC-1 cells
consequently stimulated with Epo at 0–50 U/ml for 15 min. Epo-enhanced pAkt phosporylation was detected only under conditions of serum
starvation and could be specifically inhibited by anti-EpoR antibody (+Ab) or phosphatidylinositol-3-OH kinase (PI3K) inhibitor LY2940020 (+LY). (C)
Accumulation of mRNA coding for soluble EpoR isoform (upper panel; primers: EpoR_S5/6, table 2) as compared to mRNAs coding for full-length
isoforms (two middle panels) and further related to expression of ß-actin (lower panel). 39-end-based detection of EpoR mRNA was performed with
antisense primers binding after (EpoR_FL1/2) or prior to a stop codon (EpoR_FL3/4) as visualized by a hEpoR plasmid carrying only the coding
sequence for a full-length isoform.
doi:10.1371/journal.pone.0023151.g006
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mediated Akt-phosphorylation, calling into question whether Epo
is even able to activate Akt signaling in vivo. Second, the lack of
functional consequences could result from the blockade of Epo-
binding to EpoR by sol-EpoR secreted by tumor cells [39]. Since
sol-EpoR was found in human plasma, this isoform might emerge
as an important modulator of sEpo availability for normal and
malignant cells, thus separating sEpo
high patients into a group
where sEpo will have higher chances of overcoming neutralizing
effects of sol-EpoR while reaching pancreatic or disseminated
tumor cells. A recently published mathematical model indicated
that Epo signaling is a finely tuned process in which the balance
between Epo ligand and available EpoR crucially affects receptor
activation and potentially downstream signaling in hematopoietic
cells [20]. Thus, an array of interfering factors—variability of
EpoR expression, pAkt status, and existence of the neutralizing
sol-EpoR isoform—could determine the outcome of signaling in
PDAC cells by disturbing the Epo/EpoR balance. As a result, Epo
signaling and potential pro-malignant effects would be impeded in
tumor cells of patients with a low level of sEpo, and sEPO
$16 mU/ml could represent a level of saturation sufficient to
overcome all existing limitations. This hypothesis would argue to
not administer rhEpo if sEpo levels are exceeding a critical
threshold. The testing of the available mathematical model in an
appropriate experimental system and its validation in clinical
material are further steps towards clarifying the role of the Epo/
EpoR system in PDAC and towards optimization of rhEpo-based
treatments of anemic cancer patients.
The association of high preoperative sEpo levels with
decreased survival is in line with recent findings in endometrial,
renal and non-small-cell lung cancer patients, in whom high sEpo
levels were associated with poorer outcome [15,43,44]. However,
high sEpo was also a negative prognostic factor in anemic
patients with a non-malignant condition such as congestive heart
failure [34]. Interestingly, increased mortality in these patients
was associated with sEpo levels .22.6 mU/ml—a cut-off close to
that observed in the present study (sEpo
high $16 mU/ml).
Possibly, altered Epo response is a sign of systemic disease
accompanying pancreatic disorders. Indeed, both hallmarks of
Epo expression in PDAC— ectopic expression and distant
delivery—were associated with non-malignant structures and
also found in inflammatory pancreatic disease. The inflammatory
reaction affecting the pancreas is known to alter a profile of
secreted pro-inflammatory Interleukin (IL)-1, IL6, TNFa), pro-
angiogenic (IL8, VEGF) and pro-fibrogenic (IL10, TGFb)
cytokines [35,45]. Systemic action of released cytokines might
profoundly change the vascularization, the secretion profile and
the functioning of peripheral organs. In cancer, these reactions
can be further affected by the tumor cells and yield paraneo-
plastic syndromes such as cachexia or immune dysfunction
[46,47]. Likewise, a number of factors regulating Epo expression
in hepatocytes (IL6, PHD, HIF1 a) could be produced or
influenced by primary or metastatic PDAC cells [33,46,48–50].
Our preliminary observation of an up-regulated Epo mRNA
expression in the non-metastatic hepatic specimens (not shown)
supports consideration of ectopic Epo production as a systemic
syndrome. Still, despite all similarities, the mortality of CP
patients is low. A number of recent studies showed preferential
expression of EpoR in cancer-initiating (stem) cells [51,52],
enabling a novel explanation for the negative clinical associations
of high sEpo (or administered rhEPO) through the direct effects
on tumor cells. One could speculate that systemic induction of
hepatic or vascular Epo alters the Epo gradient between the
circulation and tissues, so provoking an egress of EpoR-positive
cancer stem cells from dormant locations (bone marrow or
pancreas) into the circulation and/or from the circulation to
remote niches (pancreas or liver). Metastasized tumor cells might
further upgrade Epo synthesis at distant locations, thus
replicating the chain of events and scaling-up metastatic spread.
Consequently, the adverse outcome of Epo
high patients could be
related to the higher odds of reaching certain Epo thresholds,
which are necessary for the mobilization or recruitment of EpoR-
positive cancer (stem) cells, notwithstanding sol-EpoR. If ectopic
Epo response is inherently capped, patients having a higher Epo
response as a result of systemic disease would be pre-disposed to
early and faster development of metastasis, thus explaining how
the sEPO
high can be an independent prognostic marker and linked
to metastatic status.
In conclusion, the present study demonstrated that PDAC cells
are equipped to respond to Epo through functional EpoRs,
although conditional activation of PI3K/Akt signaling can
possibly be offset by the soluble isoform of EpoR. Despite an
impairment of the Epo-response in PDAC patients, sEpo levels
could be restored by ectopic production in capillaries and
hepatocytes. Elevation of sEPO beyond 16 mU/ml was associ-
ated with worse survival independent of metastatic status. Yet
higher levels of sEPO could be observed in stage IV patients.
Further trials are required to clarify whether high Epo
predisposes to or results from metastatic progression and whether
the suspected mobilization/recruitment of EpoR-positive cancer-
initiating cells is the likely cause of pro-malignant effects for
adverse outcome in rhEPO-treated oncologic patients. While
high serum Epo levels might be an inherited factor increasing the
probability that Epo overcomes the antagonizing effects of sol-
EpoR in PDAC patients, elucidation of the threshold determining
the outcome of the Epo/EpoR interplay by using mathematical
models might help to optimize Epo-based treatments.
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